EUVIMED · CrossrefJournal
Cancer Communications
ISSN 2523-3548 · American Association for the Advancement of Science (AAAS)
Latest articles
High-risk HPV integration reprograms cis-regulatory architecture through HPV-specific stripe transcription factors
Targeting glycolytic GARP+ fibroblasts alleviates B cell-Th2 crosstalk-driven fibrosis in pancreatic adenocarcinoma
Gastric cancer burden in the Republic of Korea from 1990 to 2021: screening versus declining Helicobacter pylori prevalence
Prophylactic Cervical Lymphadenectomy Offers No Survival Benefit in the Surgical Management of Thoracic Esophageal Cancer: 10-Year Results of the ECTOP-2002 Randomized Controlled Trial
Association of Depth of Response with Survival After Immune Checkpoint Blockade in Advanced Melanoma
A Neural-Related Transcriptional Signature Is Associated with Reduced Immune Activity and Pathological Response to Neoadjuvant Chemo-Immunotherapy in Non-Small Cell Lung Cancer
The USP28/TFAP2A/MYC/SLC7A11 axis facilitates tumorigenesis by modulating ferroptosis and serves as a nanotherapeutic target in gemcitabine-resistant bladder cancer
Unraveling the Shaping of the Microenvironment in Brain Metastasis: From Dissemination to Overt Lesions
Effectiveness of Lung Cancer Screening by Sex and Tumor Histology: Extended, Pooled Analysis of the ITALUNG and LUSI Trials, with Comparison to Findings in the NLST
CEBPB Expression in Tumor Cells Drives Immune Evasion in Colorectal Cancer via CTLA4 Up-regulation in T Cells
CEBPB-Regulated Gastric Cell Plasticity Promotes Liver Metastasis of Gastric Cancer
Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma
Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy
NSUN2 Promotes Cancer Immune Evasion via Its Moonlighting Function Acting on Metabolic Reprogramming
Erratum to “BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma”
Leveraging Innate Immune and Metabolic Cell Death Pathways in Cancer Therapies
Combined Immunotherapy and Hybrid Dose-Fraction Radiotherapy for Driver-Negative Metastatic NSCLC: A Phase II Trial with Parallel Preclinical Studies
Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK -Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial
The Spatiotemporal Heterogeneity of Tumor-Associated Stromal Cells: Reprogramming Plasticity to Unlock Precision Cancer Immunotherapy
Hypoxia-Induced Osteopontin-Positive Glioma-Associated Macrophages Facilitate Glioma Mesenchymal Transition via NF-κB Pathway Activation
Tumor Microenvironment Onmyoji: Cytokines with Dual Protumor and Antitumor Roles
Pan‐cyclin‐dependent kinase inhibition is a potential treatment for adenoid cystic carcinoma that downregulates the MYB::NFIB fusion and induces tumor regression
Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC‐WISE 01)
Harnessing chimeric antigen receptor macrophages against solid tumors
Lactylation in cancer biology: Unlocking new avenues for research and therapy
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials
Mechanism and role of regulated cell death in tumor immunity and immunotherapy
Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy
CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer
Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis
EUVIMED